J. Evan Sadler, M.D., Ph.D.

Peer-reviewed Manuscripts

• Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus EM, Sadler JE
  Multi-step binding of ADAMTS13 to VWF.
  J Thromb Haemost 2009 Sep 18; [Epub ahead of print]
• Huang J, Roth R, Heuser JE, Sadler JE
  Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress.
  Blood 2009 Feb 12;113(7):1589-97
• Gao W, Anderson PJ, Sadler JE
  Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity.
  Blood 2008 Sep 1;112(5):1713-9
• Nakayama T, Matsushita T, Yamamoto K, Mutsuga N, Kojima T, Katsumi A, Nakao N, Sadler JE, Naoe T, Saito H
  Identification of amino acid residues responsible for von Willebrand factor binding to sulfatide by charged-to-alanine-scanning mutagenesis.
  Int J Hematol 2008 May;87(4):363-70
• Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP
  von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
  Haemophilia 2008 Mar;14(2):171-232
• Huang RH, Wang Y, Roth R, Yu X, Purvis AR, Heuser JE, Egelman EH, Sadler JE
  Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor.
  Proc Natl Acad Sci U S A 2008 Jan 15;105(2):482-7
• Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE
  Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.
  Blood 2008 Jan 15;111(2):651-7
• Purvis AR, Gross J, Dang LT, Huang RH, Kapadia M, Townsend RR, Sadler JE
  Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.
  Proc Natl Acad Sci U S A 2007 Oct 2;104(40):15647-52
• Bennett CL, Kim B, Zakarija A, Bandarenko N, Pandey DK, Buffie CG, McKoy JM, Tevar AD, Cursio JF, Yarnold PR, Kwaan HC, De Masi D, Sarode R, Raife TJ, Kiss JE, Raisch DW, Davidson C, Sadler JE, Ortel TL, Zheng XL, Kato S, Matsumoto M, Uemura M, Fujimura Y
  Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.
  J Am Coll Cardiol 2007 Sep 18;50(12):1138-43
• Anderson PJ, Gailani D, Feys HB, Gao W, Majerus EM, Vanhoorelbeke K, Sadler JE
  Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma.
  Haematologica 2007 Oct;92(10):1419-22
• Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE
  Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease.
  Proc Natl Acad Sci U S A 2006 Dec 12;103(50):19099-104
• Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB
  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
  J Thromb Haemost 2006 Oct;4(10):2103-14
• Adachi T, Matsushita T, Dong Z, Katsumi A, Nakayama T, Kojima T, Saito H, Sadler JE, Naoe T
  Identification of amino acid residues essential for heparin binding by the A1 domain of human von Willebrand factor.
  Biochem Biophys Res Commun 2006 Jan 27;339(4):1178-83
• Anderson PJ, Kokame K, Sadler JE
  Zinc and calcium ions cooperatively modulate ADAMTS13 activity.
  J Biol Chem 2006 Jan 13;281(2):850-7
• Majerus EM, Anderson PJ, Sadler JE
  Binding of ADAMTS13 to von Willebrand factor.
  J Biol Chem 2005 Jun 10;280(23):21773-8
• Tao Z, Wang Y, Choi H, Bernardo A, Nishio K, Sadler JE, Lopez JA, Dong JF
  Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow.
  Blood 2005 Jul 1;106(1):141-3
• Sadler JE, Rodeghiero F
  Provisional criteria for the diagnosis of VWD type 1.
  J Thromb Haemost 2005 Apr;3(4):775-7
• Purvis AR, Sadler JE
  A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization.
  J Biol Chem 2004 Nov 26;279(48):49982-8
• Nishio K, Anderson PJ, Zheng XL, Sadler JE
  Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.
  Proc Natl Acad Sci U S A 2004 Jul 20;101(29):10578-83
• Shim K, Zhu H, Westfield LA, Sadler JE
  A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury.
  Blood 2004 Jul 15;104(2):415-9
• Zheng XL, Kaufman RM, Goodnough LT, Sadler JE
  Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
  Blood 2004 Jun 1;103(11):4043-9
• Majerus EM, Zheng X, Tuley EA, Sadler JE
  Cleavage of the ADAMTS13 propeptide is not required for protease activity.
  J Biol Chem 2003 Nov 21;278(47):46643-8
• Maita N, Nishio K, Nishimoto E, Matsui T, Shikamoto Y, Morita T, Sadler JE, Mizuno H
  Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetIn: insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins.
  J Biol Chem 2003 Sep 26;278(39):37777-81
• Zheng X, Nishio K, Majerus EM, Sadler JE
  Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
  J Biol Chem 2003 Aug 8;278(32):30136-41
• Sadler JE
  Von Willebrand disease type 1: a diagnosis in search of a disease.
  Blood 2003 Mar 15;101(6):2089-93
• Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA
  Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
  Ann Intern Med 2003 Jan 21;138(2):105-8
• Nakayama T, Matsushita T, Dong Z, Sadler JE, Jorieux S, Mazurier C, Meyer D, Kojima T, Saito H
  Identification of the regulatory elements of the human von Willebrand factor for binding to platelet GPIb. Importance of structural integrity of the regions flanked by the CYS1272-CYS1458 disulfide bond.
  J Biol Chem 2002 Jun 14;277(24):22063-72
• Richardson JL, Fuentes-Prior P, Sadler JE, Huber R, Bode W
  Characterization of the residues involved in the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor.
  Biochemistry 2002 Feb 26;41(8):2535-42
• Holzinger A, Maier EM, Buck C, Mayerhofer PU, Kappler M, Haworth JC, Moroz SP, Hadorn HB, Sadler JE, Roscher AA
  Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency.
  Am J Hum Genet 2002 Jan;70(1):20-5
• Zheng X, Sadler JE
  Mucin-like domain of enteropeptidase directs apical targeting in Madin-Darby canine kidney cells.
  J Biol Chem 2002 Mar 1;277(9):6858-63
• Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K
  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.
  J Biol Chem 2001 Nov 2;276(44):41059-63
• Bodo I, Katsumi A, Tuley EA, Eikenboom JC, Dong Z, Sadler JE
  Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins.
  Blood 2001 Nov 15;98(10):2973-9
• Goodeve AC, Eikenboom JC, Ginsburg D, Hilbert L, Mazurier C, Peake IR, Sadler JE, Rodeghiero F
  A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor.
  Thromb Haemost 2001 May;85(5):929-31
• Li CQ, Vindigni A, Sadler JE, Wardell MR
  Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin.
  J Biol Chem 2001 Mar 2;276(9):6161-8
• Richardson JL, Kroger B, Hoeffken W, Sadler JE, Pereira P, Huber R, Bode W, Fuentes-Prior P
  Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor.
  EMBO J 2000 Nov 1;19(21):5650-60
• Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A
  Impact, diagnosis and treatment of von Willebrand disease.
  Thromb Haemost 2000 Aug;84(2):160-74
• Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE
  Acquired von Willebrand syndrome: data from an international registry.
  Thromb Haemost 2000 Aug;84(2):345-9
• Katsumi A, Tuley EA, Bodo I, Sadler JE
  Localization of Disulfide Bonds in the Cystine Knot Domain of Human von Willebrand Factor.
  J Biol Chem 2000 Aug 18;275(33):25585-25594
• Zamolodchikova TS, Sokolova EA, Lu D, Sadler JE
  Activation of recombinant proenteropeptidase by duodenase.
  FEBS Lett 2000 Jan 28;466(2-3):295-9
• Matsushita T, Meyer D, Sadler JE
  Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis.
  J Biol Chem 2000 Apr 14;275(15):11044-9
• Krishnan R, Sadler JE, Tulinsky A
  Structure of the Ser195Ala mutant of human alpha--thrombin complexed with fibrinopeptide A(7--16): evidence for residual catalytic activity.
  Acta Crystallogr D Biol Crystallogr 2000 Apr;56 ( Pt 4):406-10
• Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE
  Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion.
  J Biol Chem 2000 Mar 17;275(11):7539-46
• Lu D, Futterer K, Korolev S, Zheng X, Tan K, Waksman G, Sadler JE
  Crystal structure of enteropeptidase light chain complexed with an analog of the trypsinogen activation peptide.
  J Mol Biol 1999 Sep 17;292(2):361-73
• Pejler G, Sadler JE
  Mechanism by which heparin proteoglycan modulates mast cell chymase activity.
  Biochemistry 1999 Sep 14;38(37):12187-95
• Zheng X, Lu D, Sadler JE
  Apical sorting of bovine enteropeptidase does not involve detergent- resistant association with sphingolipid-cholesterol rafts.
  J Biol Chem 1999 Jan 15;274(3):1596-605
• Xue J, Wu Q, Westfield LA, Tuley EA, Lu D, Zhang Q, Shim K, Zheng X, Sadler JE
  Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice.
  Proc Natl Acad Sci U S A 1998 Jun 23;95(13):7603-7
• Kokame K, Zheng X, Sadler JE
  Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C.
  J Biol Chem 1998 May 15;273(20):12135-9
• Hillery CA, Mancuso DJ, Sadler JE, Ponder JW, Jozwiak MA, Christopherson PA, Cox Gill J, Paul Scott J, Montgomery RR
  Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
  Blood 1998 Mar 1;91(5):1572-81
• Yuan X, Zheng X, Lu D, Rubin DC, Pung CY, Sadler JE
  Structure of murine enterokinase (enteropeptidase) and expression in small intestine during development.
  Am J Physiol 1998 Feb;274(2 Pt 1):G342-9
• Wu Q, Yu D, Post J, Halks-Miller M, Sadler JE, Morser J
  Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease.
  J Clin Invest 1998 Jan 15;101(2):321-6
• Lu D, Yuan X, Zheng X, Sadler JE
  Bovine proenteropeptidase is activated by trypsin, and the specificity of enteropeptidase depends on the heavy chain.
  J Biol Chem 1997 Dec 12;272(50):31293-300
• Xue J, Jenkins NA, Gilbert DJ, Copeland NG, Sadler JE
  Structure and localization of the thrombin receptor gene on mouse chromosome 13.
  Mamm Genome 1996 Aug;7(8):625-6
• Eikenboom JC, Matsushita T, Reitsma PH, Tuley EA, Castaman G, Briet E, Sadler JE
  Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
  Blood 1996 Oct 1;88(7):2433-41
• Englender T, Lattuada A, Mannucci PM, Sadler JE, Inbal A
  Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics.
  Blood 1996 Apr 1;87(7):2788-94
• Matsushita T, Sadler JE
  Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
  J Biol Chem 1995 Jun 2;270(22):13406-14
• Kitamoto Y, Veile RA, Donis-Keller H, Sadler JE
  cDNA sequence and chromosomal localization of human enterokinase, the proteolytic activator of trypsinogen.
  Biochemistry 1995 Apr 11;34(14):4562-8
• Inbal A, Kornbrot N, Mannucci PM, Sadler JE
  Very low frequency of "normandy type" mutations among type 1 von Willebrand disease families [letter].
  Thromb Haemost 1995 Feb;73(2):324
• Sheehan JP, Tollefsen DM, Sadler JE
  Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
  J Biol Chem 1994 Dec 30;269(52):32747-51
• Mathews II, Padmanabhan KP, Tulinksy A, Sadler JE
  Structure of a nonadecapeptide of the fifth EGF domain of thrombomodulin complexed with thrombin.
  Biochemistry 1994 Nov 22;33(46):13547-52
• Mancuso DJ, Tuley EA, Castillo R, de Bosch N, Mannucci PM, Sadler JE
  Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors.
  Thromb Haemost 1994 Aug;72(2):180-5
• Kitamoto Y, Yuan X, Wu Q, McCourt DW, Sadler JE
  Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains.
  Proc Natl Acad Sci U S A 1994 Aug 2;91(16):7588-92
• Sheehan JP, Sadler JE
  Molecular mapping of the heparin-binding exosite of thrombin.
  Proc Natl Acad Sci U S A 1994 Jun 7;91(12):5518-22
• Sadler JE
  A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
  Thromb Haemost 1994 Apr;71(4):520-5
• Dong Z, Thoma RS, Crimmins DL, McCourt DW, Tuley EA, Sadler JE
  Disulfide bonds required to assemble functional von Willebrand factor multimers.
  J Biol Chem 1994 Mar 4;269(9):6753-8
• Wu Q, Picard V, Aiach M, Sadler JE
  Activation-induced exposure of the thrombin anion-binding exosite. Interactions of recombinant mutant prothrombins with thrombomodulin and a thrombin exosite-specific antibody.
  J Biol Chem 1994 Feb 4;269(5):3725-30
• Inbal A, Kornbrot N, Harrison P, Randi AM, Sadler JE
  Effect of type IIB von Willebrand disease mutation Arg(545)Cys on platelet glycoprotein Ib binding--studies with recombinant von Willebrand factor.
  Thromb Haemost 1993 Dec 20;70(6):1058-62
• Rabinowitz I, Randi AM, Shindler KS, Tuley EA, Rustagi PK, Sadler JE
  Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
  J Biol Chem 1993 Sep 25;268(27):20497-501
• Padmanabhan K, Padmanabhan KP, Ferrara JD, Sadler JE, Tulinsky A
  The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer.
  J Biol Chem 1993 Aug 25;268(24):17651-4
• Lentz SR, Chen Y, Sadler JE
  Sequences required for thrombomodulin cofactor activity within the fourth epidermal growth factor-like domain of human thrombomodulin.
  J Biol Chem 1993 Jul 15;268(20):15312-7
• Inbal A, Englender T, Kornbrot N, Randi AM, Castaman G, Mannucci PM, Sadler JE
  Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method.
  Blood 1993 Aug 1;82(3):830-6
• Ledford MR, Rabinowitz I, Sadler JE, Kent JW, Civantos F
  New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami.
  Blood 1993 Jul 1;82(1):169-75
• Sheehan JP, Wu Q, Tollefsen DM, Sadler JE
  Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion- binding exosite determines heparin cofactor II specificity.
  J Biol Chem 1993 Feb 15;268(5):3639-45
• Ahern SM, Miyata T, Sadler JE
  Regulation of human tissue factor expression by mRNA turnover.
  J Biol Chem 1993 Jan 25;268(3):2154-9
• Lentz SR, Sadler JE
  Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum.
  Blood 1993 Feb 1;81(3):683-9
• Sadler JE, Ginsburg D
  A database of polymorphisms in the von Willebrand factor gene and pseudogene. For the Consortium on von Willebrand Factor Mutations and Polymorphisms and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
  Thromb Haemost 1993 Feb 1;69(2):185-91
• Ginsburg D, Sadler JE
  von Willebrand disease: a database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
  Thromb Haemost 1993 Feb 1;69(2):177-84
• Wu Q, Tsiang M, Sadler JE
  Localization of the single-stranded DNA binding site in the thrombin anion-binding exosite.
  J Biol Chem 1992 Dec 5;267(34):24408-12
• Shigematsu Y, Miyata T, Higashi S, Miki T, Sadler JE, Iwanaga S
  Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor VIIa.
  J Biol Chem 1992 Oct 25;267(30):21329-37
• Rabinowitz I, Tuley EA, Mancuso DJ, Randi AM, Firkin BG, Howard MA, Sadler JE
  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
  Proc Natl Acad Sci U S A 1992 Oct 15;89(20):9846-9
• Randi AM, Jorieux S, Tuley EA, Mazurier C, Sadler JE
  Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin.
  J Biol Chem 1992 Oct 15;267(29):21187-92
• Inbal A, Seligsohn U, Kornbrot N, Brenner B, Harrison P, Randi A, Rabinowitz I, Sadler JE
  Characterization of three mutations causing von Willebrand disease type IIA in five unrelated families.
  Thromb Haemost 1992 Jun 1;67(6):618-22
• Tsiang M, Lentz SR, Sadler JE
  Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity.
  J Biol Chem 1992 Mar 25;267(9):6164-70
• Wu Q, Tsiang M, Lentz SR, Sadler JE
  Ligand specificity of human thrombomodulin. Equilibrium binding of human thrombin, meizothrombin, and factor Xa to recombinant thrombomodulin.
  J Biol Chem 1992 Apr 5;267(10):7083-8
• Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler JE
  The mutation Arg (53)-->Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor.
  Blood 1992 Feb 1;79(3):563-7
• Ramos RR, Curtis BR, Sadler JE, Eby CS, Chaplin H
  Refractory immune hemolytic anemia with a high thermal amplitude, low affinity IgG anti-Pra cold autoantibody.
  Autoimmunity 1992;12(2):149-54
• Lentz SR, Sadler JE
  Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.
  J Clin Invest 1991 Dec;88(6):1906-14
• Wu QY, Sheehan JP, Tsiang M, Lentz SR, Birktoft JJ, Sadler JE
  Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin.
  Proc Natl Acad Sci U S A 1991 Aug 1;88(15):6775-9
• Tuley EA, Gaucher C, Jorieux S, Worrall NK, Sadler JE, Mazurier C
  Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.
  Proc Natl Acad Sci U S A 1991 Jul 15;88(14):6377-81
• Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE
  Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences.
  J Clin Invest 1991 Apr;87(4):1220-6
• Wagner DD, Saffaripour S, Bonfanti R, Sadler JE, Cramer EM, Chapman B, Mayadas TN
  Induction of specific storage organelles by von Willebrand factor propolypeptide.
  Cell 1991 Jan 25;64(2):403-13
• Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TL, Le Beau MM, Sorace JM, Sadler JE
  Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction.
  Biochemistry 1991 Jan 8;30(1):253-69
• Lentz SR, Tsiang M, Sadler JE
  Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms.
  Blood 1991 Feb 1;77(3):542-50
• Fressinaud E, Girma JP, Sadler JE, Baumgartner HR, Meyer D
  Synthetic RGDS-containing peptides of von Willebrand factor inhibit platelet adhesion to collagen.
  Thromb Haemost 1990 Dec 28;64(4):589-93
• Peake IR, Bowen D, Bignell P, Liddell MB, Sadler JE, Standen G, Bloom AL
  Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene.
  Blood 1990 Aug 1;76(3):555-61
• Tsiang M, Lentz SR, Dittman WA, Wen D, Scarpati EM, Sadler JE
  Equilibrium binding of thrombin to recombinant human thrombomodulIn: effect of hirudin, fibrinogen, factor Va, and peptide analogues.
  Biochemistry 1990 Nov 27;29(47):10602-12
• Peake IR, Liddell MB, Moodie P, Standen G, Mancuso DJ, Tuley EA, Westfield LA, Sorace JM, Sadler JE, Verweij CL, et al
  Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual.
  Blood 1990 Feb 1;75(3):654-61
• Scarpati EM, Sadler JE
  Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor [published erratum appears in J Biol Chem 1990 Aug 25;265(24):14696].
  J Biol Chem 1989 Dec 5;264(34):20705-13
• Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE
  Structure of the gene for human von Willebrand factor.
  J Biol Chem 1989 Nov 25;264(33):19514-27
• Silverman GA, Ye RD, Pollock KM, Sadler JE, Korsmeyer SJ
  Use of yeast artificial chromosome clones for mapping and walking within human chromosome segment 18q21.3.
  Proc Natl Acad Sci U S A 1989 Oct;86(19):7485-9
• Espinosa R 3d, Sadler JE, Le Beau MM
  Regional localization of the human thrombomodulin gene to 20p12-cen.
  Genomics 1989 Oct;5(3):649-50
• Ye RD, Ahern SM, Le Beau MM, Lebo RV, Sadler JE
  Structure of the gene for human plasminogen activator inhibitor-2. The nearest mammalian homologue of chicken ovalbumin.
  J Biol Chem 1989 Apr 5;264(10):5495-502
• Cohen RL, Niclas J, Lee WM, Wun TC, Crowley CW, Levinson AD, Sadler JE, Shuman MA
  Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation.
  J Biol Chem 1989 May 15;264(14):8375-83
• Dittman WA, Kumada T, Sadler JE, Majerus PW
  The structure and function of mouse thrombomodulin. Phorbol myristate acetate stimulates degradation and synthesis of thrombomodulin without affecting mRNA levels in hemangioma cells.
  J Biol Chem 1988 Oct 25;263(30):15815-22
• Ye RD, Wun TC, Sadler JE
  Mammalian protein secretion without signal peptide removal. Biosynthesis of plasminogen activator inhibitor-2 in U-937 cells.
  J Biol Chem 1988 Apr 5;263(10):4869-75
• Scarpati EM, Sadler JE, O'Connell P, Nakamura Y, Leppert M, Ballard L, Lathrop GM, Lalouel JM, White R
  Identification and mapping of RFLPs for human tissue factor (HTF) to chromosome 1p.
  Nucleic Acids Res 1987 Nov 11;15(21):9098
• O'Connell P, Lathrop GM, Law M, Leppert M, Nakamura Y, Hoff M, Kumlin E, Thomas W, Elsner T, Ballard L, Goodman P, Azen E, Sadler JE, Lai GY, Lalouel J-M, White R
  A primary genetic linkage map for human chromosome 12.
  Genomics 1987; 1: 93-102
• Scarpati EM, Wen D, Broze GJ Jr, Miletich JP, Flandermeyer RR, Siegel NR, Sadler JE
  Human tissue factor: cDNA sequence and chromosome localization of the gene.
  Biochemistry 1987 Aug 25;26(17):5234-8
• Wen DZ, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE
  Human thrombomodulIn: complete cDNA sequence and chromosome localization of the gene.
  Biochemistry 1987 Jul 14;26(14):4350-7
• Shelton-Inloes BB, Broze GJ Jr, Miletich JP, Sadler JE
  Evolution of human von Willebrand factor: cDNA sequence polymorphisms, repeated domains, and relationship to von Willebrand antigen II.
  Biochem Biophys Res Commun 1987 Apr 29;144(2):657-65
• Ye RD, Wun TC, Sadler JE
  cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta.
  J Biol Chem 1987 Mar 15;262(8):3718-25
• Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE
  Gene deletions correlate with the development of alloantibodies in von Willebrand disease.
  J Clin Invest 1987 May;79(5):1459-65
• Murray JC, Buetow KH, Donovan M, Hornung S, Motulsky AG, Disteche C, Dyer K, Swisshelm K, Anderson J, Giblett E, Sadler E, Eddy R, Shows TB
  Linkage disequilibrium of plasminogen polymorphisms and assignment of the gene to human chromosome 6q26-6q27.
  Am J Hum Genet 1987; 40: 338-350
• Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K
  Amino acid sequence of human von Willebrand factor.
  Biochemistry 1986 Jun 3;25(11):3171-84
• Shelton-Inloes BB, Titani K, Sadler JE
  cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms.
  Biochemistry 1986 Jun 3;25(11):3164-71
• Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW
  Cloning and characterization of two cDNAs coding for human von Willebrand factor.
  Proc Natl Acad Sci U S A 1985 Oct;82(19):6394-8
• Malinowski DP, Sadler JE, Davie EW
  Characterization of a complementary deoxyribonucleic acid coding for human and bovine plasminogen.
  Biochemistry 1984 Aug 28;23(18):4243-50
• Beyer TA, Sadler JE, Hill RL
  Purification to homogeneity of H blood group beta-galactoside alpha 1 leads to 2 fucosyltransferase from porcine submaxillary gland.
  J Biol Chem 1980 Jun 10;255(11):5364-72
• Beyer TA, Rearick JI, Paulson JC, Prieels JP, Sadler JE, Hill RL
  Biosynthesis of mammalian glycoproteins. Glycosylation pathways in the synthesis of the nonreducing terminal sequences.
  J Biol Chem 1979 Dec 25;254(24):12531-4
• Sadler JE, Rearick JI, Hill RL
  Purification to homogeneity and enzymatic characterization of an alpha- N-acetylgalactosaminide alpha 2 leads to 6 sialyltransferase from porcine submaxillary glands.
  J Biol Chem 1979 Jul 10;254(13):5934-41
• Rearick JI, Sadler JE, Paulson JC, Hill RL
  Enzymatic characterization of beta D-galactoside alpha2 leads to 3 sialyltransferase from porcine submaxillary gland.
  J Biol Chem 1979 Jun 10;254(11):4444-51
• Sadler JE
  The calculation of some physical parameters of proteins from sucrose density gradient centrifugation data.
  J Biol Chem 1979 Jun 10;254(11):4443
• Sadler JE, Rearick JI, Paulson JC, Hill RL
  Purification to homogeneity of a beta-galactoside alpha2 leads to 3 sialyltransferase and partial purification of an alpha-N- acetylgalactosaminide alpha2 leads to 6 sialyltransferase from porcine submaxillary glands.
  J Biol Chem 1979 Jun 10;254(11):4434-42
• Paulson JC, Sadler JE, Hill RL
  Restoration of specific myxovirus receptors to asialoerythrocytes by incorporation of sialic acid with pure sialyltransferases.
  J Biol Chem 1979 Mar 25;254(6):2120-4
• Sadler JE, Paulson JC, Hill RL
  The role of sialic acid in the expression of human MN blood group antigens.
  J Biol Chem 1979 Mar 25;254(6):2112-9
• Schwartz J, Sadler JE
  Ring 'flipping' in bis(cyclo-octatetraene)titanium(II); an organometallic intramolecular redox reaction which involves only the geometrical deformation of organic ligands.
  JCS ChemCommun 1973; 172-173